131 related articles for article (PubMed ID: 21782798)
1. Characterization of ADAM28 as a biomarker of bladder transitional cell carcinomas by urinary proteome analysis.
Yang MH; Chu PY; Chen SC; Chung TW; Chen WC; Tan LB; Kan WC; Wang HY; Su SB; Tyan YC
Biochem Biophys Res Commun; 2011 Aug; 411(4):714-20. PubMed ID: 21782798
[TBL] [Abstract][Full Text] [Related]
2. Urinary protein profiling by liquid chromatography/tandem mass spectrometry: ADAM28 is overexpressed in bladder transitional cell carcinoma.
Tyan YC; Yang MH; Chen SC; Jong SB; Chen WC; Yang YH; Chung TW; Liao PC
Rapid Commun Mass Spectrom; 2011 Oct; 25(19):2851-62. PubMed ID: 21913264
[TBL] [Abstract][Full Text] [Related]
3. Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis.
Sheng KH; Yao YC; Chuang SS; Wu H; Wu TF
Proteomics; 2006 Feb; 6(3):1058-65. PubMed ID: 16400682
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
5. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of ADAM12 in human bladder cancer.
Fröhlich C; Albrechtsen R; Dyrskjøt L; Rudkjaer L; Ørntoft TF; Wewer UM
Clin Cancer Res; 2006 Dec; 12(24):7359-68. PubMed ID: 17189408
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
9. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients.
Chen CL; Lai YF; Tang P; Chien KY; Yu JS; Tsai CH; Chen HW; Wu CC; Chung T; Hsu CW; Chen CD; Chang YS; Chang PL; Chen YT
J Proteome Res; 2012 Dec; 11(12):5611-29. PubMed ID: 23082778
[TBL] [Abstract][Full Text] [Related]
10. High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion.
Eiján AM; Sandes EO; Riveros MD; Thompson S; Pasik L; Mallagrino H; Celeste F; Casabé AR
Cancer; 2003 Jul; 98(2):262-8. PubMed ID: 12872343
[TBL] [Abstract][Full Text] [Related]
11. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
[TBL] [Abstract][Full Text] [Related]
12. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis.
Tolson JP; Flad T; Gnau V; Dihazi H; Hennenlotter J; Beck A; Mueller GA; Kuczyk M; Mueller CA
Proteomics; 2006 Jan; 6(2):697-708. PubMed ID: 16252305
[TBL] [Abstract][Full Text] [Related]
13. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
14. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
15. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder.
Tong GX; Yee H; Chiriboga L; Hernandez O; Waisman J
Hum Pathol; 2005 Jul; 36(7):741-6. PubMed ID: 16084942
[TBL] [Abstract][Full Text] [Related]
16. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
18. Bladder squamous cell carcinomas express psoriasin and externalize it to the urine.
Celis JE; Rasmussen HH; Vorum H; Madsen P; Honoré B; Wolf H; Orntoft TF
J Urol; 1996 Jun; 155(6):2105-12. PubMed ID: 8618345
[TBL] [Abstract][Full Text] [Related]
19. Searching cell-secreted proteomes for potential urinary bladder tumor markers.
Lin CY; Tsui KH; Yu CC; Yeh CW; Chang PL; Yung BY
Proteomics; 2006 Aug; 6(15):4381-9. PubMed ID: 16819731
[TBL] [Abstract][Full Text] [Related]
20. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
